Please use this identifier to cite or link to this item:
Title: Prevention strategies to identify LASA errors: building and sustaining a culture of patient safety
Author: Lizano Díez, Irene
Figueiredo Escribá, Carlos de
Piñero López, Maria Ángeles
Fernández Lastra, Cecilia
Mariño Hernández, Eduardo L.
Modamio Charles, Pilar
Keywords: Medicaments
Seguretat dels pacients
Prescripció de medicaments
Equivalència terapèutica dels medicaments
Patients safety
Drug prescribing
Therapeutic equivalency in drugs
Issue Date: 29-Jan-2020
Publisher: BioMed Central
Abstract: Background: Potential look-alike, sound-alike (LASA) errors in outpatient and inpatient prescriptions have been widely described worldwide. However, most strategies of reducing drug name confusion have been only focused on the processes of prescribing and dispensing, often following local rules. Main text: An illustrative recent example about this topic is given: the antidepressant Brintellix® (vortioxetine)(Takeda Pharmaceuticals USA, Inc.) and the antiplatelet medication Brilinta® (ticagrelor) (AstraZeneca LP). Revision of the initiatives that are currently applied to prevent potential LASA errors in different countries around the world and debate about the emerging strategies that could be implemented in short and mid-term. At present, a common policy worldwide on the authorization of unique names for innovative medicines does not exist. The implication of authorities in topdown strategies and the importance of developing an international health policy on the authorization of unique names for innovative medicines are highlighted in the following piece of opinion. Conclusions: Building and sustaining a culture of patient safety should be considered as a global top-down strategy which involved all the elements in the system (regulatory bodies, manufacturers and suppliers). The precedent established by the FDA in prevention strategies to identify and avoid LASA errors has been extremely important and should lead to international discussion. Coordinated international efforts are urgently needed in this area for the sake of patients' safety.
Note: Reproducció del document publicat a:
It is part of: BMC Health Services Research, 2020, vol. 20, num. 63
Related resource:
ISSN: 1472-6963
Appears in Collections:Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)

Files in This Item:
File Description SizeFormat 
695168.pdf487.9 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons